Leadership & Pay ·
Valion Bio, Inc. announced the termination of CEO Michael K. Handley effective August 16, 2026, and appointed CFO Lisa…
VBIOValion Bio, Inc.
Valion Bio, Inc. announced the termination of CEO Michael K. Handley effective August 16, 2026, and appointed CFO Lisa Wolf as Chief Operating Officer on the same date. The company entered into a letter agreement with 3i, LP to issue 1,500 shares of Series B Preferred Stock at $1,000 per share for an aggregate purchase price of $1,500,000, closing around August 17, 2026. Concurrently, a royalty agreement was executed granting investors 5% of gross revenue from subsidiary Velocity Bioworks, Inc. for ten years. At a Special Meeting on August 14, 2026, shareholders approved granting the Board discretionary authority to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50 within twelve months. Valion Bio, Inc. operates in the biotechnology sector.